News & Media

282025-03

Mabgeek Biotech has officially moved into WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY

172025-07

Mabgeek Biotech has submitted an application for listing on the Hong Kong Stock Exchange.

On July 14th, Mabgeek Biotech submitted an application for a Hong Kong IPO, with CICC serving as the
282025-03

Mabgeek Biotech has officially moved into WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY

On March 27th, the signing ceremony for the settlement of Mabgeek Biotech in WORLO COMPUTING-CHANGSH
092025-01

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma The

Technological innovation

Efficient integration; Establish an efficient antigen-antibody expression and purification platform.

All team members come from well-known domestic pharmaceutical companies, and the team has over three years of cooperation experience.

The company has a 500-square-meter laboratory and four cell culture rooms.

Independent R&D and clinical development of innovative antibodies have resulted in the first domestic market launch and the first global submission.

About Us

About
R&D
- Areas
- Pipeline
- Platforms
Publications
- MG-K10
- MG-ZG122
Careers
- Culture
- Join Us

Contact Us

ADD:No.5, Building 34, Lane 122, Chunxiao Road, Zhangjiang Town, Pudong New Area, Shanghai
TEL: +86-21-51371305
EMAlL:info@mabgeek.com

All Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com

湘ICP备2024096314号公安部备案：31011502015815